Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRANSREG: Low-Dose IL-2 in Autoimmune Diseases
NCT01988506Phase 2Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Jan 2014
- Primary completion
- Oct 2019
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
A Phase 2 trial of aldesleukin in rheumatoid arthritis (RA), ankylosing spondylitis (AS), systemic lupus erythematosus (SLE), psoriasis, Behçet's disease (BD), sponsored by Assistance publique - Hôpitaux de Paris. Started Jan 2014; status: completed.
02
Drugs
aldesleukin
03
Conditions
rheumatoid arthritis (RA)ankylosing spondylitis (AS)systemic lupus erythematosus (SLE)psoriasisBehçet's disease (BD)
Beyond the preview
Go deeper on NCT01988506.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01988506.